Developing new treatments for muscular dystrophy using RNA technology
(Project 2) Development of U7snRNA Vectors for Dystrophinopathy
This study is exploring new ways to help people with muscular dystrophies, like Duchenne and Becker muscular dystrophy, by using special tools to improve the production of a protein called dystrophin, which is important for muscle health, and it aims to create personalized treatments based on each person's unique genetic makeup.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project ID | NIH-10992527 on NIH RePORTER |
What this research studies
This research focuses on creating innovative vectors that can alter RNA splicing to improve the production of dystrophin protein in patients with muscular dystrophies, particularly Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). By utilizing a personalized medicine approach, the study aims to tailor therapies based on individual genetic mutations, potentially allowing for the expression of full-length dystrophin in patients with specific mutations. The methodology involves using adeno-associated virus (AAV) vectors to deliver these therapeutic agents effectively to muscle cells. The goal is to enhance the efficacy of existing treatments and provide better outcomes for patients with these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Duchenne muscular dystrophy or Becker muscular dystrophy, particularly those with specific genetic mutations that can be targeted by the developed therapies.
Not a fit: Patients with muscular dystrophies that do not have mutations amenable to the proposed RNA splicing alterations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for muscular dystrophy, improving muscle function and quality of life for affected patients.
How similar studies have performed: Previous research has shown promise in using RNA-based therapies for muscular dystrophies, indicating that this approach has the potential for success.
Where this research is happening
Columbus, United States
- Research Inst Nationwide Children's Hosp — Columbus, United States (Active)
Researchers
- Principal investigator: Flanigan, Kevin M — Research Inst Nationwide Children's Hosp
- Study coordinator: Flanigan, Kevin M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.